Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been assigned an average rating of “Hold” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $10.67.
A number of brokerages recently issued reports on CRVS. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 15th. Roth Capital began coverage on Corvus Pharmaceuticals in a research report on Wednesday, May 29th. They issued a “buy” rating and a $6.00 price objective on the stock.
In related news, major shareholder Holdings A/S Novo sold 39,716 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $5.32, for a total value of $211,289.12. Following the transaction, the insider now owns 4,380,800 shares of the company’s stock, valued at $23,305,856. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc bought 657,344 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average cost of $3.72 per share, for a total transaction of $2,445,319.68. The disclosure for this purchase can be found here. In the last three months, insiders purchased 880,690 shares of company stock worth $3,223,227. 40.40% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in Corvus Pharmaceuticals by 6.6% in the second quarter. Renaissance Technologies LLC now owns 833,098 shares of the company’s stock valued at $3,116,000 after acquiring an additional 51,398 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Corvus Pharmaceuticals by 6.1% during the second quarter. Vanguard Group Inc. now owns 487,636 shares of the company’s stock valued at $1,824,000 after buying an additional 28,239 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Corvus Pharmaceuticals by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 336,327 shares of the company’s stock valued at $1,234,000 after buying an additional 75,626 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Corvus Pharmaceuticals by 304.0% during the fourth quarter. Deutsche Bank AG now owns 207,782 shares of the company’s stock valued at $762,000 after buying an additional 156,346 shares during the last quarter. Finally, Fosun International Ltd grew its stake in shares of Corvus Pharmaceuticals by 7.7% during the second quarter. Fosun International Ltd now owns 184,116 shares of the company’s stock valued at $624,000 after buying an additional 13,142 shares during the last quarter. 84.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of CRVS stock traded up $0.21 on Friday, reaching $4.13. The company’s stock had a trading volume of 5,197 shares, compared to its average volume of 223,261. The company has a debt-to-equity ratio of 0.03, a quick ratio of 9.17 and a current ratio of 9.17. Corvus Pharmaceuticals has a 12-month low of $3.22 and a 12-month high of $11.23. The company has a 50 day simple moving average of $4.77.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.02). On average, sell-side analysts forecast that Corvus Pharmaceuticals will post -1.59 EPS for the current fiscal year.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.